Novartis’ Cosentyx (secukinumab) Receives the MHRA’s Marketing Authorisation for Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis
- Cosentyx has received the marketing authorization from the MHRA as monothx. or in combination with MTX for ERA & JPsA in patients aged 6yrs.
- The authorization was based on the P-III (JUNIPERA) trial evaluating Cosentyx vs PBO in 86 children & adolescents aged 2–18yrs. which showed a significantly longer time to flare, a 72% reduction in risk of flare for 2yrs., more patients achieved & maintained JIA ACR score along with a reduction in joint symptoms. The safety profile was consistent with the known safety profile of secukinumab
- The extension study of secukinumab is currently ongoing to evaluate the long-term efficacy, safety & tolerability for the same indication. Cosentyx is 1st fully human biologic that inhibits interleukin-17A
Ref: Pharmiweb | Image: Novartis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.